Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14568395 | 1.00 | CA12 (0.36) | CA12CA9CA1CA2CHRM2 | |
| SCHEMBL27934891 | 1.00 | CA12 (0.36) | CA12CA9CA1CA2CHRM2 | |
| SCHEMBL18487527 | 0.78 | RECQL (0.31) | — | |
| SCHEMBL8354298 | 0.77 | CA12 (0.42) | CA12CA9CA1CA2CHRM2 | |
| SCHEMBL942938 | 0.77 | CA12 (0.42) | CA12CA9CA1CA2CHRM2 | |
| SCHEMBL17696628 | 0.73 | CA12 (0.33) | CA12CA9CA1CA2CHRM2 | |
| SCHEMBL5492216 | 0.73 | — | — | |
| SCHEMBL2541143 | 0.73 | CA12 (0.40) | CA12CA9CA1CA2CHRM2 | |
| SCHEMBL2541139 | 0.73 | CA12 (0.40) | CA12CA9CA1CA2CHRM2 | |
| SCHEMBL11414567 | 0.71 | CA12 (0.41) | CA12CA9CA1CA2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349860-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | CA12 4660/4885CA9 4026/4885CA1 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.